A Study of RNK08954 in Subjects With Advanced Solid Tumors With KRAS ((Kirsten Rat Sarcoma) G12D Mutation

This is a first in human (FIH), Phase 1/2 open-label multi-center, dose escalation and expansion study to evaluate the safety, tolerability and pharmacokinetics of RNK08954 to determine the optimal dose and recommended dose for expansion and evaluate clinical activity in patients with advanced solid tumors with KRAS G12D mutation. This is a 2-part study: dose exploration/indication expansion and dose optimization ( to identify a dose that preserves clinical benefit with optimal tolerability).

Trial Details

NCT ID
NCT06667544
Phase
PHASE1 / PHASE2
Sponsor
Ranok Therapeutics (Hangzhou) Co., Ltd.
Status
RECRUITING
Cancer Type
Sarcoma
Interventions
  • RNK08954-01
Locations (sample)
  • Nanning, Guangxi, China|22.81667,108.31667
  • Zhengzhou, Henan, China|34.75778,113.64861
  • Wuhan, Hubei, China|30.58333,114.26667
  • Hangzhou, Zhejiang, China|30.29365,120.16142
  • Shanghai, China|31.22222,121.45806

Key Eligibility Criteria

  • Must be 18 years of age or older.
  • Must have pathologically documented locally advanced or metastatic malignancy harboring KRAS G12D mutations identified through deoxyribonucleic aci…
  • Must have received prior standard therapy appropriate for their tumor type, or in the opinion of the investigator, would be unlikely to derive furt…
  • Must have measurable lesion(s) per Response Evaluation Criteria in Solid Tumours (RECIST) version 1.1 by Computed tomography (CT) scan with contras…

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Sarcoma Trials on Trialify →